Digital Storytelling as a Psychosocial Tool for Adult Cancer Survivors.

Digital Storytelling as a Psychosocial Tool for Adult Cancer Survivors. Oncol Nurs Forum. 2019 Mar 01;46(2):147-154 Authors: Laing CM, Moules NJ, Sinclair S, Estefan A Abstract PURPOSE: To understand the meaning and impact for adult patients with cancer (past or present) of creating a digital story related to their cancer experience. PARTICIPANTS & SETTING: 10 participants made digital stories with the help of a research assistant trained in digital storytelling. This research took place in a large, urban center in Calgary, Alberta, Canada. METHODOLOGIC APPROACH: This research was done in the tradition of philosophical hermeneutics. Ten one-on-one interviews were conducted, and data were analyzed using an interpretive qualitative methodology. FINDINGS: Findings revealed that digital stories were cathartic; reconnected individuals with family, friends, and parts of their lives that had been interrupted from cancer therapy; helped participants reflect in a way that was often described as therapeutic; and bridged communication with others about their cancer experiences. IMPLICATIONS FOR NURSING: Digital stories can be used to highlight the immense psychosocial impact of cancer and point healthcare professionals and other researchers toward creative and nontraditional ways to address this issue. PMID: 30767963 [PubMed - in process]
Source: Oncology Nursing Forum - Category: Nursing Authors: Tags: Oncol Nurs Forum Source Type: research

Related Links:

Publication date: December 2019Source: Materials Science and Engineering: C, Volume 105Author(s): Mohammad Ansari, Ashkan Bigham, Hossein Abbastabar AhangarAbstractSpinel ferrite-based nanoparticles are being widely applied in bone tissue regeneration because of their outstanding properties such as their capability to be applied in hyperthermia-based bone cancer therapy. In the present study, Cu0.3Zn0.2Mg0.5Fe2O4 nanoparticles are synthesized through thermal-treatment method followed by calcination at 650 °C. The calcined nanoparticles are characterized through X-ray diffraction (XRD), field-emission scanning electro...
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
Publication date: December 2019Source: Materials Science and Engineering: C, Volume 105Author(s): Buddolla Anantha Lakshmi, Sanghyo KimAbstractNanostructured metal-organic frameworks (N-MOFs) are crystalline coordination nanopolymers in which metals are conjugated with organic and inorganic linker molecules. At present, N-MOFs have attracted significant interest owing to their intrinsically high porosity and ultrahigh surface areas, which allow them to be loaded with a broad array of materials, including drug molecules. In addition, N-MOFs possess other unique properties, such as good mobility, high reactivity, outstanding...
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
Publication date: Available online 17 August 2019Source: Chinese Chemical LettersAuthor(s): Shuai Wang, Dandan Shen, Lijie Zhao, Xiaohan Yuan, Jialing Cheng, Bin Yu, Yichao Zheng, Hongmin LiuAbstractTargeting bromodomain-containing protein 4 (BRD4) has been proved to be an effective strategy for cancer therapy. To date, numerous BRD4 inhibitors and degraders have been identified, some of which have advanced into clinical trials. In this work, a focused library of new [1,2,4]triazolo[1,5-a]pyrimidine derivatives were discovered to be able to inhibit BRD4. WS-722 inactivated BRD4 (BD1/BD2), BRD2 (BD1/BD2) and BRD3 (BD1/BD2) ...
Source: Chinese Chemical Letters - Category: Chemistry Source Type: research
In conclusion, our data show how oncogenic and tumor-suppressive drivers of cellular senescence act to regulate surveillance processes that can be circumvented to enable SnCs to elude immune recognition but can be reversed by cell surface-targeted interventions to purge the SnCs that persist in vitro and in patients. Since eliminating SnCs can prevent tumor progression, delay the onset of degenerative diseases, and restore fitness; since NKG2D-Ls are not widely expressed in healthy human tissues and NKG2D-L shedding is an evasion mechanism also employed by tumor cells; and since increasing numbers of B cells express NKG2D ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Authors: Abdellatif AAH Abstract Numerous normal and tumors cells are well-known to express the somatostatin receptors (SSTRs) on their surface which make the receptor be useful for tumor scintigraphy. Thus, identification of SSTRs is beneficial, especially SSTR2. The somatostatin analogue, Octreotide (OCT) was chosen as a ligand, as it is known to selectively bind to SSTR2. Moreover, polyethylene glycol (PEG), 8armPEG was used as a branched PEG to provide a low non-specific cell binding and easily chemical modification. OCT, and fluorescein (Flu) were conjugated to branched PEG using a water-soluble carbodiimide (...
Source: Drug Development and Industrial Pharmacy - Category: Drugs & Pharmacology Tags: Drug Dev Ind Pharm Source Type: research
Publication date: Available online 17 August 2019Source: Seminars in Cancer BiologyAuthor(s): Jan Budczies, Klaus Kluck, Wolfgang Walther, Ulrike SteinAbstractMetastasis remains the key issue impacting cancer patient survival and failure or success of cancer therapies. Metastatic spread is a complex process including dissemination of single cells or collective cell migration, penetration of the blood or lymphatic vessels and seeding at a distant organ site. Hundreds of genes involved in metastasis have been identified in studies across numerous cancer types. Here, we analyzed how the metastasis-associated gene MACC1 cooper...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
ConclusionsWe obtained health utility and HRQoL scores of Japanese PC patients stratified by disease progression in detail. Our results will be useful for establishing cost-effectiveness analyses in Japanese PC settings.
Source: Quality of Life Research - Category: Health Management Source Type: research
CONCLUSION: Studies related to the anti-inflammatory and anticancer potential of apigenin have been explored through this review article. Moreover, the patent analysis of apigenin has further strengthened its therapeutic role. Probing into the therapeutic properties of apigenin, further add value to this molecule in terms of its down regulation of major inflammatory and cancer associated signaling pathways. The article simultaneously would assist the scientific community to precisely understand the role of apigenin and design novel anti-cancer therapies. PMID: 31418666 [PubMed - as supplied by publisher]
Source: Recent Patents on Inflammation and Allergy Drug Discovery - Category: Allergy & Immunology Tags: Recent Pat Inflamm Allergy Drug Discov Source Type: research
Authors: Strand MS, Krasnick BA, Pan H, Zhang X, Bi Y, Brooks C, Wetzel C, Sankpal N, Fleming T, Goedegebuure SP, DeNardo DG, Gillanders WE, Hawkins WG, Wickline SA, Fields RC Abstract Over 95% of pancreatic adenocarcinomas (PDACs), as well as a large fraction of other tumor types, such as colorectal adenocarcinoma, are driven by KRAS activation. However, no direct RAS inhibitors exist for cancer therapy. Furthermore, the delivery of therapeutic agents of any kind to PDAC in particular has been hindered by the extensive desmoplasia and resultant drug delivery challenges that accompanies these tumors. Small interfer...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Immune checkpoint inhibitors (ICI) are new cancer drugs that target immune checkpoints, molecules acting as regulators of the immune system, boosting the immune response against cancer cells. Currently approved ICI block cytotoxic T-lymphocyte antigen-4 and programmed death (PD)-1 and PD ligand-1. Since their introduction in cancer therapy, ICI had great impact on treatment and prognosis of different cancers. As highlighted by US estimates, ICI are increasingly being used in cancer population, with the percentage of eligible patients for ICI increasing from 1.5% in 2011 to 43.6% in 2018 [1].
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Editorial Source Type: research
More News: Canada Health | Cancer | Cancer & Oncology | Cancer Therapy | Nurses | Nursing